Enrollment completed for our Phase 2 clinical trial in Alport syndrome

Published on 31/01/2025

ENYO Pharma is very proud to announce the successful completion of patient enrollment in ALPESTRIA-1, our Phase 2 clinical trial evaluating Vonafexor in Alport syndrome across the U.S. and Europe.

This major milestone was achieved with the last-patient-in dosed ahead of schedule. The study timelines were accelerated thanks to a tailored strategy based on a very strong and effective collaboration with our partners Natera and Accelsiors, all clinical sites in the US, France ans Spain with investigators, clinical research coordinators and site managers, and the associations of Alport syndrome patients ASF, FEDERG, AIRG-France, AIRG-España.

ENYO Pharma would like to sincerely thank all the stakeholders involved in the study for their excellent work and support. We look forward to presenting topline data in Q4-2025.

To know more about the study, please visit:

Read next in 'Latest news'

• La Phase 2
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH